-
Something wrong with this record ?
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
J. Schetelig, P. Chevallier, M. van Gelder, J. Hoek, O. Hermine, R. Chakraverty, P. Browne, N. Milpied, M. Malagola, G. Socié, J. Delgado, E. Deconinck, G. Damaj, S. Maury, D. Beelen, SN. Quoc, P. Shankara, A. Brecht, J. Mayer, M. Hunault-Berger,...
Language English Country Great Britain
Document type Journal Article
NLK
Free Medical Journals
from 1997 to 1 year ago
Freely Accessible Science Journals
from 1997 to 1 year ago
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
- MeSH
- Quinazolinones MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell * drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Graft vs Host Disease * MeSH
- Transplantation Conditioning MeSH
- Purines MeSH
- Retrospective Studies MeSH
- Hematopoietic Stem Cell Transplantation * MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53mut/del CLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II-IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted.
Birmingham Heartlands Hospital Birmingham UK
Bone Marrow Transplant Unit ASST Spedali Civili di Brescia University of Brescia Brescia Italy
Centre Hospitalier Universitaire de Lille LIRIC INSERM U995 Université de Lille Lille France
Centre Hospitalier Universitaire Institut d'Hématologie Normandie University Caen France
EBMT Data Office Leiden The Netherlands
Helios Dr Horst Schmidt Kliniken Wiesbaden Germany
Hope Directorate Dublin Ireland
Hopital Jean Minjoz Besancon France
Hopital la Pitié Salpêtrière Universite Paris 4 Paris France
Hospital Clinic Barcelona Spain
Inserm U1245 and Department of Hematology Centre Henri Becquerel Normandie University Rouen France
Maladies du Sang CHU Angers Angers France
Medical Clinic 1 University Hospital Dresden Germany
Service d'Hématologie Clinique et de Thérapie Cellulaire Creteil CHU Henri Mondor Créteil France
University Hospital Brno Brno Czech Republic
University Hospital Eppendorf Hamburg Germany
University Hospital Essen Germany
University Hospital Maastricht Maastricht The Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025993
- 003
- CZ-PrNML
- 005
- 20211026133318.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-020-01069-w $2 doi
- 035 __
- $a (PubMed)33004942
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Schetelig, Johannes $u Medical Clinic I, University Hospital, Dresden, Germany. johannes.schetelig@uniklinikum-dresden.de $u DKMS, Dresden, Germany. johannes.schetelig@uniklinikum-dresden.de
- 245 10
- $a Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party / $c J. Schetelig, P. Chevallier, M. van Gelder, J. Hoek, O. Hermine, R. Chakraverty, P. Browne, N. Milpied, M. Malagola, G. Socié, J. Delgado, E. Deconinck, G. Damaj, S. Maury, D. Beelen, SN. Quoc, P. Shankara, A. Brecht, J. Mayer, M. Hunault-Berger, J. Bittenbring, C. Thieblemont, S. Lepretre, H. Baldauf, LC. de Wreede, O. Tournilhac, I. Yakoub-Agha, N. Kröger, P. Dreger
- 520 9_
- $a No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53mut/del CLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II-IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted.
- 650 12
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chronická lymfatická leukemie $x farmakoterapie $7 D015451
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a puriny $7 D011687
- 650 _2
- $a chinazolinony $7 D052999
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a příprava pacienta k transplantaci $7 D019172
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Chevallier, Patrice $u CHU Nantes, Nantes, France
- 700 1_
- $a van Gelder, Michel $u University Hospital Maastricht, Maastricht, The Netherlands
- 700 1_
- $a Hoek, Jennifer $u EBMT Data Office, Leiden, The Netherlands
- 700 1_
- $a Hermine, Olivier $u Department of Hematology, Necker Hospital and INSERM U1163 Imagine Institute, University of Paris, Paris, France
- 700 1_
- $a Chakraverty, Ronjon $u Cancer Institute and Institute of Immunity and Transplantation, University College London Hospital, London, UK
- 700 1_
- $a Browne, Paul $u Hope Directorate, Dublin, Ireland
- 700 1_
- $a Milpied, Noel $u CHU Bordeaux, Pessac, France
- 700 1_
- $a Malagola, Michele $u Bone Marrow Transplant Unit, ASST-Spedali Civili di Brescia, University of Brescia, Brescia, Italy
- 700 1_
- $a Socié, Gerard $u Hopital St. Louis, Paris, France
- 700 1_
- $a Delgado, Julio $u Hospital Clinic, Barcelona, Spain
- 700 1_
- $a Deconinck, Eric $u Hopital Jean Minjoz, Besancon, France
- 700 1_
- $a Damaj, Ghandi $u Centre Hospitalier-Universitaire, Institut d'Hématologie, Normandie University, Caen, France
- 700 1_
- $a Maury, Sebastian $u Service d'Hématologie Clinique et de Thérapie Cellulaire Creteil, CHU Henri Mondor, Créteil, France
- 700 1_
- $a Beelen, Dietrich $u University Hospital, Essen, Germany
- 700 1_
- $a Quoc, Stéphanie Nguyen $u Hopital la Pitié-Salpêtrière, Universite Paris IV, Paris, France
- 700 1_
- $a Shankara, Paneesha $u Birmingham Heartlands Hospital, Birmingham, UK
- 700 1_
- $a Brecht, Arne $u Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Germany
- 700 1_
- $a Mayer, Jiri $u University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Hunault-Berger, Mathilde $u Maladies du Sang, CHU Angers, Angers, France
- 700 1_
- $a Bittenbring, Jörg $u University of Saarland, Homburg, Saar, Germany
- 700 1_
- $a Thieblemont, Catherine $u Hôpital St. Louis, Paris, France
- 700 1_
- $a Lepretre, Stéphane $u Inserm U1245 and Department of Hematology, Centre Henri Becquerel, Normandie University, Rouen, France
- 700 1_
- $a Baldauf, Henning $u DKMS, Dresden, Germany
- 700 1_
- $a de Wreede, Liesbeth C $u Department of Medical Statistics & Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Tournilhac, Olivier $u Service Therapie Cellulaire & Hematologie Cliniquer, Centre Hospitalier Universitaire, Clermont Ferrand, France
- 700 1_
- $a Yakoub-Agha, Ibrahim $u Centre Hospitalier Universitaire de Lille, LIRIC, INSERM U995, Université de Lille, Lille, France
- 700 1_
- $a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany
- 700 1_
- $a Dreger, Peter $u University of Heidelberg, Heidelberg, Germany
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 56, č. 3 (2021), s. 605-613
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33004942 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133324 $b ABA008
- 999 __
- $a ok $b bmc $g 1714871 $s 1146500
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 56 $c 3 $d 605-613 $e 20201002 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20211013
